Last reviewed 2026-04-23 · How we verify

Methyl Prednisolone (MP)

Sana'a University · Phase 3 active Small molecule

Methyl Prednisolone (MP) is a Corticosteroid Small molecule drug developed by Sana'a University. It is currently in Phase 3 development for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (such as psoriasis or eczema).

Methylprednisolone is a synthetic corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines.

Methylprednisolone is a synthetic corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines. Used for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (such as psoriasis or eczema).

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Methyl Prednisolone (MP)
Sponsor	Sana'a University
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

It works by binding to glucocorticoid receptors in the cytoplasm, which then translocate to the nucleus and inhibit the transcription of inflammatory genes. This leads to a decrease in the production of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, resulting in reduced inflammation and immune response.

Approved indications

Severe asthma attacks
Severe allergic reactions (anaphylaxis)
Severe skin conditions (such as psoriasis or eczema)
Severe inflammatory conditions (such as rheumatoid arthritis or lupus)

Common side effects

Nausea
Headache
Dizziness
Insomnia
Increased appetite
Weight gain
Osteoporosis
Glaucoma
Cataracts
Hypokalemia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Methyl Prednisolone (MP) CI brief — competitive landscape report
Methyl Prednisolone (MP) updates RSS · CI watch RSS
Sana'a University portfolio CI

Frequently asked questions about Methyl Prednisolone (MP)

What is Methyl Prednisolone (MP)?

Methyl Prednisolone (MP) is a Corticosteroid drug developed by Sana'a University, indicated for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (such as psoriasis or eczema).

How does Methyl Prednisolone (MP) work?

Methylprednisolone is a synthetic corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines.

What is Methyl Prednisolone (MP) used for?

Methyl Prednisolone (MP) is indicated for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (such as psoriasis or eczema), Severe inflammatory conditions (such as rheumatoid arthritis or lupus).

Who makes Methyl Prednisolone (MP)?

Methyl Prednisolone (MP) is developed by Sana'a University (see full Sana'a University pipeline at /company/sana-a-university).

What drug class is Methyl Prednisolone (MP) in?

Methyl Prednisolone (MP) belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Methyl Prednisolone (MP) in?

Methyl Prednisolone (MP) is in Phase 3.

What are the side effects of Methyl Prednisolone (MP)?

Common side effects of Methyl Prednisolone (MP) include Nausea, Headache, Dizziness, Insomnia, Increased appetite, Weight gain.

Drug class: All Corticosteroid drugs
Manufacturer: Sana'a University — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Severe asthma attacks
Indication: Drugs for Severe allergic reactions (anaphylaxis)
Indication: Drugs for Severe skin conditions (such as psoriasis or eczema)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing